Embodiments of the present disclosure relate to bone cement injection systems, and, in certain embodiments, provide systems and methods for on-demand control of bone cement viscosity for treating vertebral compression fractures and for preventing cement extravasation.
Osteoporotic fractures are prevalent in the elderly, with an annual estimate of 1.5 million fractures in the United States alone. These include 750,000 vertebral compression fractures (VCFs) and 250,000 hip fractures. The annual cost of osteoporotic fractures in the United States has been estimated at $13.8 billion. The prevalence of VCFs in women age 50 and older has been estimated at about 26%. The prevalence increases with age, reaching approximately 40% among 80-year-old women. Medical advances aimed at slowing or arresting bone loss from aging have not provided solutions to this problem. Further, the population affected will grow steadily as life expectancy increases. Osteoporosis affects the entire skeleton but most commonly causes fractures in the spine and hip. Spinal or vertebral fractures also cause other serious side effects, with patients suffering from loss of height, deformity and persistent pain which can significantly impair mobility and quality of life. Fracture pain usually lasts 4 to 6 weeks, with intense pain at the fracture site. Chronic pain often occurs when one vertebral level is greatly collapsed or multiple levels are collapsed.
Postmenopausal women are predisposed to fractures, such as in the vertebrae, due to a decrease in bone mineral density that accompanies postmenopausal osteoporosis. Osteoporosis is a pathologic state that literally means “porous bones”. Skeletal bones are made up of a thick cortical shell and a strong inner meshwork, or cancellous bone, with collagen, calcium salts, and other minerals. Cancellous bone is similar to a honeycomb, with blood vessels and bone marrow in the spaces. Osteoporosis describes a condition of decreased bone mass that leads to fragile bones which are at an increased risk for fractures. In an osteoporosis bone, the sponge-like cancellous bone has pores or voids that increase in dimension making the bone very fragile. In young, healthy bone tissue, bone breakdown occurs continually as the result of osteoclast activity, but the breakdown is balanced by new bone formation by osteoblasts. In an elderly patient, bone resorption can surpass bone formation thus resulting in deterioration of bone density. Osteoporosis occurs largely without symptoms until a fracture occurs.
Vertebroplasty and kyphoplasty are recently developed techniques for treating vertebral compression fractures. Percutaneous vertebroplasty was first reported by a French group in 1987 for the treatment of painful hemangiomas. In the 1990's, percutaneous vertebroplasty was extended to indications including osteoporotic vertebral compression fractures, traumatic compression fractures, and painful vertebral metastasis. Vertebroplasty is the percutaneous injection of PMMA (polymethyl methacrylate) into a fractured vertebral body via a trocar and cannula. The targeted vertebra is identified under fluoroscopy. A needle is introduced into the vertebral body under fluoroscopic control, to allow direct visualization. A bilateral transpedicular (through the pedicle of the vertebra) approach is typical but the procedure can be done unilaterally. The bilateral transpedicular approach allows for more uniform PMMA infill of the vertebra.
In a bilateral approach, approximately 1 to 4 ml of PMMA is used on each side of the vertebra. Since the PMMA needs to be forced into the cancellous bone, the techniques require high pressures and fairly low viscosity cement. Since the cortical bone of the targeted vertebra may have a recent fracture, there is also the potential for PMMA leakage. The PMMA cement contains radiopaque materials so that, when injected under live fluoroscopy, cement localization and leakage can be observed. The visualization of PMMA injection and extravasation are critical to the technique, enabling the physician to terminate PMMA injection when leakage is evident. The cement is injected using syringes to allow the physician manual control of injection pressure.
Kyphoplasty is a modification of percutaneous vertebroplasty. Kyphoplasty involves a preliminary step including the percutaneous placement of an inflatable balloon tamp in the vertebral body. Inflation of the balloon creates a cavity in the bone prior to cement injection. The proponents of percutaneous kyphoplasty have suggested that high pressure balloon-tamp inflation can at least partially restore vertebral body height. In kyphoplasty, some physicians state that PMMA can be injected at a lower pressure into the collapsed vertebra since a cavity exists, when compared to conventional vertebroplasty.
The principal indications for any form of vertebroplasty are osteoporotic vertebral collapse with debilitating pain. Radiography and computed tomography are performed in the days preceding treatment to determine the extent of vertebral collapse, the presence of epidural or foraminal stenosis caused by bone fragment retropulsion, the presence of cortical destruction or fracture and the visibility and degree of involvement of the pedicles.
Leakage of PMMA during vertebroplasty can result in very serious complications, including compression of adjacent structures that may necessitate emergency decompressive surgery. See “Anatomical and Pathological Considerations in Percutaneous Vertebroplasty and Kyphoplasty: A Reappraisal of the Vertebral Venous System”, Groen, R. et al, Spine Vol. 29, No. 13, pp 1465-1471 2004. Leakage or extravasation of PMMA is a critical issue and can be divided into paravertebral leakage, venous infiltration, epidural leakage, and intradiscal leakage. The exothermic reaction of PMMA carries potential catastrophic consequences if thermal damage extends to the dural sac, cord, and nerve roots. Surgical evacuation of leaked cement in the spinal canal has been reported. It has been found that leakage of PMMA is related to various clinical factors such as the vertebral compression pattern, the extent of the cortical fracture, bone mineral density, the interval from injury to operation, the amount of PMMA injected, and the location of the injector tip. In one recent study, close to 50% of vertebroplasty cases resulted in leakage of PMMA from the vertebral bodies. See Hyun-Woo Do et al, “The Analysis of Polymethylmethacrylate Leakage after Vertebroplasty for Vertebral Body Compression Fractures”, J. of Korean Neurosurg. Soc. Vol. 35, No. 5 (May 2004) pp. 478-82.
Another recent study was directed to the incidence of new VCFs adjacent to the vertebral bodies that were initially treated. Vertebroplasty patients often return with new pain caused by a new vertebral body fracture. Leakage of cement into an adjacent disc space during vertebroplasty increases the risk of a new fracture of adjacent vertebral bodies. See Am. J. Neuroradiol. 2004 February; 25(2):175-80. The study found that about 58% of vertebral bodies adjacent to a disc with cement leakage fractured during the follow-up period compared with about 12% of vertebral bodies adjacent to a disc without cement leakage.
Another life-threatening complication of vertebroplasty is pulmonary embolism. See Bernhard, J. et al, “Asymptomatic diffuse pulmonary embolism caused by acrylic cement: an unusual complication of percutaneous vertebroplasty”, Ann. Rheum. Dis. 2003; 62:85-86. The vapors from PMMA preparation and injection also are cause for concern. See Kirby, B, et al., “Acute bronchospasm due to exposure to polymethylmethacrylate vapors during percutaneous vertebroplasty”, Am. J. Roentgenol. 2003; 180:543-544.
In both higher pressure cement injection (vertebroplasty) and balloon-tamped cementing procedures (kyphoplasty), the methods do not provide for well controlled augmentation of vertebral body height. The direct injection of bone cement simply follows the path of least resistance within the fractured bone. The expansion of a balloon applies also compacting forces along lines of least resistance in the collapsed cancellous bone. Thus, the reduction of a vertebral compression fracture is not optimized or controlled in high pressure balloons as forces of balloon expansion occur in multiple directions.
In a kyphoplasty procedure, the physician often uses very high pressures (e.g., up to about 200 or 300 psi) to inflate the balloon, which may crush and compact cancellous bone. Expansion of the balloon under high pressures close to cortical bone can also fracture the cortical bone, typically the endplates, which can cause regional damage to the cortical bone with the risk of cortical bone necrosis. Such cortical bone damage is highly undesirable as the endplate and adjacent structures provide nutrients for the disc.
Kyphoplasty also does not provide a distraction mechanism capable of 100% vertebral height restoration. Further, the kyphoplasty balloons under very high pressure typically apply forces to vertebral endplates within a central region of the cortical bone that may be weak, rather than distributing forces over the endplate.
Certain embodiments of the invention provide bone cement injectors and control systems that allow for vertebroplasty procedures that inject cement having a substantially constant viscosity over an extended cement injection interval.
A computer controller is provided to control cement flow parameters in the injector and energy delivery parameters for selectively accelerating polymerization of bone cement before the cement contacts the patient's body.
In accordance with one embodiment, a bone treatment system is provided. The system comprises a bone fill material injector system comprising an injector configured to be at least partially introduced into a bone. The system also comprises a thermal energy emitter operatively coupled to the injector system and configured for delivering energy to a flow of bone fill material through the injector system. An electronic controller is configured to modulate the delivery of energy from the thermal energy emitter to the flow of bone fill material based at least in part on a sensed pressure in the injector system to achieve a desired bone fill material viscosity.
In accordance with another embodiment, a method for treating bone is provided. The method comprises flowing bone fill material through a bone fill material injector system having at least a portion of an injector positioned in a cancellous bone portion of the bone, delivering energy to the flow of bone fill material via a thermal energy emitter in communication with the bone fill material injector system, and electronically controlling the delivery of energy to the thermal energy emitter to achieve a desired bone fill material viscosity based at least in part on a sensed pressure in the bone fill material injector system.
In accordance with still another embodiment, a bone treatment system is provided. The system comprises a handle component in communication with one or more energy sources, and a sleeve component having a proximal portion attached to the handle component and a distal end configured for positioning in a bone, the handle and sleeve components defining a flow channel extending therethrough. The system also comprises a first energy emitter configured for delivering energy to a bone fill material flow in a flow channel portion in the handle component, and a second energy emitter configured for delivering energy to a bone fill material flow in a flow channel portion in the sleeve component.
In accordance with yet another embodiment, a method for treating a bone is provided. The method comprises inserting at least a portion of an injector of a bone cement injector system within a vertebral body, providing a flow of a settable bone cement having a first viscosity into a proximal portion of the injector, and applying energy to the bone cement via a thermal energy emitter of the bone cement injector system to cause the viscosity of the bone cement to change from the first viscosity to a second viscosity, different than the first viscosity. The method also comprises urging the bone cement having the second viscosity from the proximal portion toward the distal portion of the injector, applying energy to the bone cement via another thermal energy emitter of the bone cement injector system disposed within the injector to cause the flow of bone cement exiting an outlet of the injector to achieve a third viscosity, different than the first and second viscosities, and introducing the bone cement with said third viscosity into cancellous bone.
These and other objects of the present invention will become readily apparent upon further review of the following drawings and specification.
In order to better understand embodiments of the present disclosure and to see how they may be carried out in practice, selected embodiments are next described, by way of non-limiting examples only, with reference to the accompanying drawings, in which like reference characters denote corresponding features consistently throughout similar embodiments in the attached drawings.
Reference will now be made to the embodiments illustrated in the drawings and accompanying text. As background, a vertebroplasty procedure using embodiments of the present disclosure would introduce the injector of
The terms “bone cement, bone fill or fill material, infill material or composition” includes its ordinary meaning as known to those skilled in the art and may include any material for infilling a bone that includes an in-situ hardenable or settable cement, or a composition that can be infused with such a hardenable cement. The fill material also can include other “fillers” including, but not limited to, filaments, microspheres, powders, granular elements, flakes, chips, tubules and the like, autograft or allograft materials, as well as other chemicals, pharmacological agents or other bioactive agents.
The term “flowable material” includes its ordinary meaning as known to those skilled in the art and may include a material continuum that is unable to withstand a static shear stress and responds with an irrecoverable flow (e.g., a fluid), unlike an elastic material or elastomer that responds to shear stress with a recoverable deformation. Flowable material includes fill materials or composites that include a first component (e.g., a fluid) and a second component that may include an elastic or inelastic material component that responds to stress with a flow, no matter the proportions of the first and second component, and where the above shear test does not apply to the second component alone.
The terms “substantially” or “substantial” mean largely but not entirely. For example, substantially may mean about 50% to about 99.999%, about 80% to about 99.999% or about 90% to about 99.999%.
The term “vertebroplasty” includes its ordinary meaning as known to those skilled in the art and may include any procedure wherein fill material is delivered into the interior of a vertebra.
The term “cancellous bone”, also known as “spongy bone” includes its ordinary meaning as known to those skilled in the art and may include a porous bone having a honeycombed or spongy appearance that encloses naturally occurring, pre-existing spaces filled with bone marrow, the honeycomb-like structure organized into a three-dimensional matrix or lattice of bony processes, called trabeculae, arranged along lines of stress.
The term “cortical bone”, also known as “compact bone” includes its ordinary meaning as known to those skilled in the art and includes the dense outer surface of bones that forms a protective layer around the internal bone including cancellous bone.
The term “osteoplasty” includes its ordinary meaning as known to those skilled in the art and may include any procedure wherein fill material is delivered into the interior of a bone.
In
Referring to
Now turning to the cut-away view of
Referring to
In other embodiments, the thermal energy emitter 110 can be a PTCR constant temperature heater as described above or selected from the group of emitters consisting of at least one of a resistive heater, a fiber optic emitter, a light channel, an ultrasound transducer, an electrode and an antenna. Accordingly in any such embodiment, the energy source 140 can comprise at least one of a voltage source, a radiofrequency source, an electromagnetic energy source, a non-coherent light source, a laser source, an LED source, a microwave source, a magnetic source and an ultrasound source that is operatively coupled to the emitter 110.
Referring
In one embodiment shown in
Still referring to
In one embodiment, the surface area of an interface 200 between the actuator member 175 and pressurized flow media 188 is substantially larger than the surface area of an interface 200′ between the actuator member 175 and bone cement 130 to thereby provide pressure amplification between the pressurizable chamber 185 and chamber 132 of the cement source or syringe. In one embodiment as indicated in
Referring to
Referring to
In one embodiment, the bone treatment system includes a bone cement injector system including a thermal energy emitter 110 for delivering energy to the bone cement in the injector system, a controller 145 for modulating applied energy from the emitter to thereby control a curing reaction of the cement, and a sensor system operatively coupled to the injector system for measuring an operational parameter of bone cement within the system. In
In another embodiment, referring to
In another embodiment, the bone cement system and more particularly the cement mixing assembly 275 of
In another embodiment, the bone cement system 10 includes a sensor that measures and indicates the bone cement flow rate within the flow passageway in the injector system. In the embodiment of
In further embodiments, one or more of the sensors 270, 272, 276, 282, 285, 288, 290 may be in communication with the controller 145 for input of data collected by the sensors into the controller 145. For example, in certain embodiments, an operator may obtain at least a portion of the data collected by the sensors 270, 272, 276, 282, 285, 288, 290 and manually input the relevant data into the controller 145. In alternative embodiments, one or more of the sensors 270, 272, 276, 282, 285, 288, 290 may possess a direct connection, such as a wired or wireless data connection with the controller 145, whereby the controller 145 may request data from the sensors 270, 272, 276, 282, 285, 288, 290 and/or the sensors 270, 272, 276, 282, 285, 288, 290 may communicate at least a portion of collected data to the controller 145.
Now turning to
Still referring to
Now turning to
As can be seen in
Now turning to
Thus,
This aspect of the invention allows, for the first time, a controlled and substantially constant viscosity cement at a selected viscosity level that is selected to inhibit (e.g., prevent) extravasation. This aspect of the inventive bone cement 130 and system 10 is advantageous in that a typical treatment of a vertebral compression fracture requires cement injection over a period of several minutes, for example from about 2 to 10 minutes, about 2 to 6 minutes, or about 2 to 4 minutes. The physician typically injects a small amount of bone cement, for example about 1 or 2 cc's, then pauses cement injection in order to image the injected cement to check for extravasation, then repeats the additional cement injection and imaging operations as necessary. For example, in a non-limiting embodiment, the injection and imaging operations may be repeated from about 2 to 10 times or more, where the complete treatment interval can take about 4 to 6 minutes or more. It can be easily understood that a cement with a working time of at least about 5-6 minutes is needed for a typical treatment of a VCF, otherwise the first batch of cement would be too advanced in the curing process (see
With continued reference to
Thus, in one embodiment of the present disclosure, the bone cement system includes: first and second sources for causing a controlled curing reaction in a bone cement, where the first source includes a predetermined exothermic curing reaction in response to mixing cement precursor compositions and the second source includes a thermal energy emitter 110 for providing a variable curing reaction in the cement, and a controller 145 for modulating applied energy from the thermal energy emitter 110 to thereby control the curing reaction over a selected working time.
It can be understood from U.S. Provisional Application No. 60/899,487, filed on Feb. 5, 2007, titled Bone Treatment Systems and Methods and U.S. patent application Ser. No. 12/024,969, filed Feb. 1, 2008, titled Bone Treatment Systems and Methods, that PMMA cement compositions can be created to provide highly-extended working times. Such bone cements in combination with the system 10 of embodiments of the present disclosure thus allow for selected working times of at least 6 minutes, 8 minutes, 10 minutes, 12 minutes, 14 minutes, 16 minutes, 18 minutes, 20 minutes, 25 minutes. Further embodiments provide a control system that allows for providing a bone cement within a selected cement viscosity range as it exits the injector outlet 122 over the selected working time. Further embodiments provide a controller that is capable of providing a substantially constant cement viscosity over the selected working time. Additional embodiments provide a controller that is capable of providing a plurality of selected time-viscosity profiles of the cement as it exits the injector.
In one embodiment of the present disclosure, the bone cement system includes: first and second sources for causing a controlled curing reaction in a bone cement, where the first source includes a predetermined exothermic curing reaction in response to mixing cement precursor compositions and the second source includes thermal energy applied to the bone cement from an external source, and a control system that controls the thermal energy applied by the external source so as to provide a cement exiting the injector a selected viscosity of at least 600 Pa·s, 800 Pa·s, 1000 Pa·s, 1200 Pa·s, 1400 Pa·s, 1600 Pa·s, 1800 Pa·s, 2000 Pa·s, 2500 Pa·s, 3000 Pa·s, 4000 Pa·s, or at least 5,000 Pa·s.
In another embodiment, the present disclosure provides a method of preparing a curable bone cement for injection into a vertebra. The method includes mixing bone cement precursors such that a first non-variable curing reaction occurs between the precursors in the bone cement and applying energy to the bone cement from an external source to provide a second variable curing reaction in the bone cement, wherein applied energy from the second source is controlled by a controller to permit a combination non-variable and variable curing reaction thereby providing a selected cement viscosity. Further, the method includes varying the applied energy from the second source in response to the length of a post-mixing interval. Further, the method includes varying the applied energy from the second source in response to ambient temperature that is measured by a temperature sensor in the system. Further, the method includes varying the applied energy from the second source in response to a selected injection rate of the bone cement flow through the system. Further, the method includes varying the applied energy from the second source to provide a bone cement having an injection viscosity of at least 500 Pa·s, 1000 Pa·s, 1500 Pa·s, 2000 Pa·s, 3000 Pa·s, 4000 Pas or 5000 Pa·s.
In another embodiment, the present disclosure provides a method of preparing a curable bone cement for injection into a vertebra that includes mixing bone cement precursors thereby causing a first curing reaction characterizing the cement with a first time-viscosity profile, and actuating a controller to controllably apply energy to the bone cement from an external source, thereby modifying the first time-viscosity profile to a second time-viscosity profile, and injecting the cement having the second time-viscosity profile into the vertebra. In this method, the cement viscosity is at least 500 Pascals-second, 1000 Pa·s, 1500 Pa·s, 2000 Pa·s, 3000 Pa·s, 4000 Pa·s or at least 5000 Pa·s. The method includes actuating the controller to modulate applied energy in response to control signals selected from the group consisting of the length of a cement post-mixing interval, ambient temperature, cement temperature, and rate of cement injection.
As can be understood from
In another embodiment, a bone treatment system can include a bone cement injector system, a thermal energy emitter for delivering energy to a flow of bone cement through the injector system and a controller including an algorithm for modulating applied energy from the emitter to a bone cement flow, wherein the algorithm is increases the applied energy from zero at a rate selected to inhibit vaporization of monomer portions of the bone cement.
In another embodiment of the present disclosure, the controller 145 allows for a physician to select a particular approximate cement viscosity by use of a selector mechanism operatively connected to the controller 145. In one embodiment, the physician can select among a plurality of substantially constant viscosities that can be delivered over the working time, for example, a first choice may include viscosities less than 1,000 Pa·s, and a second choice may include viscosities in excess of 1,500 Pa·s. It should be appreciated that the selections can range from two to six or more, with each selection being a viscosity range useful for a particular purpose.
In another embodiment of the present disclosure, referring to
Similarly,
In another embodiment, referring to
In one embodiment of the system, the bone cement 130 has a predetermined working time for polymerizing from an initial state to a selected endpoint of at least 10 minutes, 12 minutes, 14 minutes, 16 minutes, 18 minutes, 20 minutes, 25 minutes, 30 minutes and 40 minutes, as disclosed in Provisional application Ser. No. 60/899,487 filed Feb. 5, 2007 titled Bone Treatment Systems and Methods. In an embodiment, the selected endpoint may include providing the bone cement 130 in a partly polymerized condition having a viscosity within a selected viscosity range that substantially inhibits cement extravasation. In a non-limiting embodiment, extravasation may be inhibited when the bone cement viscosity is greater than about 2000 Pa·s.
The energy source 140 may accelerate a polymerization rate of the bone cement by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% and 95% over that which would be achieved absent application of energy to the bone cement from the energy source. In another embodiment, the energy source 140 and controller 145 may accelerate the polymerization rate of the cement such that the selected endpoint of the bone cement is achieved in less than 1 second, 5 seconds, 10 seconds, 20 seconds, 30 seconds, 45 seconds, 60 seconds and 2 minutes.
In an embodiment of a method of using the system 10 of
In another embodiment of the method, the energy-delivery emitter 110 is actuated by the operator from a location outside any imaging field.
In a further embodiment of the method, the energy-delivery emitter 110 may be actuated to apply energy of at least 0.01 Watt, 0.05 Watt, 0.10 Watt, 0.50 Watt and 1.0 Watt. In another aspect of the method, the applied energy is modulated by controller 145. In another aspect of the method, the energy source and controller may accelerate the polymerization rate of the bone cement to reach the selected endpoint in less than 1 second, 5 seconds, 10 seconds, 20 seconds, 30 seconds, 45 seconds, 60 seconds and 2 minutes. In another aspect of the method, the energy source and controller may accelerate the polymerization rate of the bone cement by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% and 95%.
In another embodiment of the present disclosure, a method of bone cement injection accordingly includes modulating the rate of cement flow in response to determining a selected parameter of the cement flow such as flow rate. The method of bone cement injection further included applying and modulating thermal energy application from an emitter in the injector body to the cement flow. The method of bone cement injection further includes modulating the application of energy in response to signals that relate to a selected parameter such as flow rate of the cement flow.
Of particular interest, another embodiment of a method of bone cement injection includes (a) providing a bone cement injector body carrying a PTCR (positive temperature coefficient of resistance) material in a flow channel therein, (b) applying a selected level of energy to a cement flow through the PTCR material, and (c) utilizing an algorithm that processes impedance values of the PTCR material to determine the cement flow rate. The method of bone cement injection further includes modulating a cement injection parameter in response to the processed impedance values.
Another embodiment of a method of bone cement injection includes (a) providing a bone cement injector body carrying a PTCR material or other thermal energy emitter in a flow channel therein, (b) causing a selected cement flow rate and a selected level of energy delivery to the cement flow through the emitter, and (c) modulating the selected flow rate and/or energy delivery to maintain a substantially constant impedance value of the emitter material over a cement injection interval. The selected cement injection interval can be at least 1 minute, at least 5 minutes, at least 10 minutes and at least 15 minutes.
In another embodiment, of the method, the selected flow rate and/or energy delivery may be modulated to maintain a substantially constant viscosity of bone cement ejected from the injector over a cement injection interval. The system and energy source may apply energy of at least 0.01 Watt, 0.05 Watt, 0.10 Watt, 0.50 Watt and 1.0 Watt. In another aspect, the energy source and controller may accelerate polymerization rate of the bone cement to a selected endpoint in less than 1 second, 5 seconds, 10 seconds, 20 seconds, 30 seconds, 45 seconds, 60 seconds and 2 minutes.
Another embodiment of a method of bone cement injection utilizes systems such as system 10 and 400 as described above and include (a) providing a bone cement injector body with a flow channel extending therethrough from a proximal handle end though a medial portion to a distal end portion having a flow outlet, (b) causing cement flow through the flow channel, and (c) warming the cement flow with an energy emitter in a proximal end or medial portion thereof to initiate or accelerate polymerization of the cement of the cement flow. The method may further include providing a flow rate of the cement flow that ranges from 0.1 cc/minute to 20 cc/minute, from 0.2 cc/minute to 10 cc/minute, and from 0.5 cc/minute to 5 cc/minute.
Of particular interest, embodiments of the above-described methods of bone cement injection provide delivery of bone cement at a predetermined cement flow rate so as to allow cement flows a selected interval over which they are allowed to polymerize in the flow channel downstream from the energy emitter. This method includes providing a selected interval of greater than 1 second, greater than 5 seconds, greater than 10 seconds, greater than 20 seconds, and greater than 60 seconds.
The above-described method utilizes an energy emitter that applies energy sufficient to elevate the temperature of the bone cement by at least 1° C., at least 2° C., and at least 5° C. The method of bone cement injection includes utilizing an energy emitter that applies at least 0.1 Watt of energy to the cement flow, at least 0.5 Watt of energy to the cement flow, and at least 1.0 Watt of energy to the cement flow. The method includes the flow rate of the cement flow being adjusted in intervals by controller 145, or being continuously adjusted by a controller.
The above disclosed embodiments are intended to be illustrative and not exhaustive. Particular characteristics, features, dimensions, and the like that are presented in dependent claims can be combined and fall within the scope of the invention. The invention also encompasses embodiments as if dependent claims were alternatively written in a multiple dependent claim format with reference to other independent claims. Specific characteristics and features of the invention and its method are described in relation to some figures and not in others, and this is for convenience only. While the principles of the invention have been made clear in the embodiments described above, it will be obvious to those skilled in the art that modifications may be utilized in the practice of the invention, and otherwise, which are particularly adapted to specific environments and operative requirements without departing from the principles of the invention. The appended claims are intended to cover and embrace any and all such modifications, with the limits only of the true purview, spirit and scope of the invention.
Of course, the foregoing description is that of certain features, aspects and advantages of the present invention, to which various changes and modifications can be made without departing from the spirit and scope of the present invention. Moreover, the bone treatment systems and methods need not feature all of the objects, advantages, features and aspects discussed above. Thus, for example, those skill in the art will recognize that the invention can be embodied or carried out in a manner that achieves or optimizes one advantage or a group of advantages as taught herein without necessarily achieving other objects or advantages as may be taught or suggested herein. In addition, while a number of variations of the invention have been shown and described in detail, other modifications and methods of use, which are within the scope of this invention, will be readily apparent to those of skill in the art based upon this disclosure. It is contemplated that various combinations or sub-combinations of these specific features and aspects of embodiments may be made and still fall within the scope of the invention. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combined with or substituted for one another in order to form varying modes of the discussed bone treatment systems and methods.
This application is a continuation of U.S. application Ser. No. 14/741,864, filed Jun. 17, 2015, entitled Bone Treatment Systems and Methods, which is a divisional of U.S. Application Ser. No. 12/345,937, filed Dec. 30, 2008, entitled Bone Treatment Systems And Methods, now U.S. Pat. No. 9,066,769, which claims the benefit of priority under 35 U.S.C. § 119(e) of U.S. Provisional Applications: No. 61/009,699, filed on Dec. 31, 2007, entitled Bone Treatment Systems And Methods; No. 61/009,659, filed on Dec. 31, 2007, entitled Bone Treatment Systems And Methods; No. 61/009,671, filed on Dec. 31, 2007, entitled Bone Treatment Systems And Methods; and No. 61/009,673, filed on Dec. 31, 2007, entitled Bone Treatment Systems And Methods, each of which is hereby incorporated by reference in its entirety and should be considered a part of this specification. This application is further related to the following U.S. patent application Ser. No. 11/209,035 filed Aug. 22, 2005, titled Bone Treatment Systems and Methods; Provisional Application No. 60/842,805 filed Sep. 7, 2006 titled Bone Treatment Systems and Methods; No. 60/713,521 filed Sep. 1, 2005 titled Bone Treatment Systems and Methods; No. 60/929,936 filed Apr. 30, 2007 titled Bone Treatment Systems and Methods and No. 60/899,487 filed Feb. 5, 2007 titled Bone Treatment Systems and Methods. The entire contents of all of the above applications are hereby incorporated by reference and should be considered a part of this specification.
Number | Name | Date | Kind |
---|---|---|---|
3349840 | Tope et al. | Oct 1967 | A |
4250887 | Dardik et al. | Feb 1981 | A |
4265618 | Herskovitz et al. | May 1981 | A |
4294251 | Grennwald et al. | Oct 1981 | A |
4338925 | Miller | Jul 1982 | A |
4377168 | Rzasa et al. | Mar 1983 | A |
4735625 | Davidson | Apr 1988 | A |
4772287 | Ray et al. | Sep 1988 | A |
4815454 | Dozier | Mar 1989 | A |
4963151 | Ducheyene et al. | Oct 1990 | A |
4969888 | Scholten et al. | Nov 1990 | A |
4969906 | Kronman | Nov 1990 | A |
5037437 | Matsen, III | Aug 1991 | A |
5108404 | Scholten et al. | Apr 1992 | A |
5145250 | Planck et al. | Sep 1992 | A |
5324305 | Kanner | Jun 1994 | A |
5431654 | Nic | Jul 1995 | A |
5514135 | Earle | May 1996 | A |
5542928 | Evans et al. | Aug 1996 | A |
5679299 | Gilbert et al. | Oct 1997 | A |
5693099 | Harle | Dec 1997 | A |
5788711 | Lehner et al. | Aug 1998 | A |
5806528 | Magliochetti | Sep 1998 | A |
5814681 | Hino et al. | Sep 1998 | A |
5954716 | Sharkey et al. | Sep 1999 | A |
6048346 | Reiley et al. | Apr 2000 | A |
6075067 | Lidgren | Jun 2000 | A |
6077256 | Mann | Jun 2000 | A |
6122549 | Sharkey et al. | Sep 2000 | A |
6171312 | Beaty | Jan 2001 | B1 |
6228072 | Omaleki et al. | May 2001 | B1 |
6231615 | Preissman | May 2001 | B1 |
6235043 | Reiley et al. | May 2001 | B1 |
6236020 | Friedman | May 2001 | B1 |
6248110 | Reiley et al. | Jun 2001 | B1 |
6261289 | Levy | Jul 2001 | B1 |
6264659 | Ross et al. | Jul 2001 | B1 |
6280456 | Scribner et al. | Aug 2001 | B1 |
6284809 | Plummer et al. | Sep 2001 | B1 |
6309420 | Preissman | Oct 2001 | B1 |
6312254 | Friedman | Nov 2001 | B1 |
6316885 | Collins et al. | Nov 2001 | B1 |
6319255 | Grundei et al. | Nov 2001 | B1 |
6332894 | Stalcup et al. | Dec 2001 | B1 |
6348055 | Preissman | Feb 2002 | B1 |
6358254 | Anderson | Mar 2002 | B1 |
6383190 | Preissman | May 2002 | B1 |
6425923 | Stalcup et al. | Jul 2002 | B1 |
6436143 | Ross | Aug 2002 | B1 |
6439439 | Rickard et al. | Aug 2002 | B1 |
6440138 | Reiley et al. | Aug 2002 | B1 |
6443988 | Felt et al. | Sep 2002 | B2 |
6447514 | Stalcup et al. | Sep 2002 | B1 |
6485436 | Truckai et al. | Nov 2002 | B1 |
6524102 | Davis | Feb 2003 | B2 |
6558428 | Park | May 2003 | B2 |
6575331 | Peeler et al. | Jun 2003 | B1 |
6610079 | Li et al. | Aug 2003 | B1 |
6613054 | Scribner et al. | Sep 2003 | B2 |
6632235 | Weikel et al. | Oct 2003 | B2 |
6662969 | Peeler et al. | Dec 2003 | B2 |
6676664 | Al-Assir | Jan 2004 | B1 |
6706069 | Berger | Mar 2004 | B2 |
6712852 | Chung et al. | Mar 2004 | B1 |
6716216 | Boucher et al. | Apr 2004 | B1 |
6719773 | Boucher et al. | Apr 2004 | B1 |
6723095 | Hammerslag | Apr 2004 | B2 |
6726691 | Osorio et al. | Apr 2004 | B2 |
6736537 | Coffeen et al. | May 2004 | B2 |
6740093 | Hochschuler et al. | May 2004 | B2 |
6753358 | Fischer et al. | Jun 2004 | B2 |
6767936 | Walz et al. | Jul 2004 | B2 |
6783515 | Miller et al. | Aug 2004 | B1 |
6814736 | Reiley et al. | Nov 2004 | B2 |
6832988 | Sproul | Dec 2004 | B2 |
6863672 | Reiley et al. | Mar 2005 | B2 |
6899713 | Shaolian et al. | May 2005 | B2 |
6923813 | Phillips | Aug 2005 | B2 |
6929640 | Underwood et al. | Aug 2005 | B1 |
6957747 | Peeler et al. | Oct 2005 | B2 |
6964667 | Shaolian et al. | Nov 2005 | B2 |
6979341 | Scribner et al. | Dec 2005 | B2 |
6979352 | Reynolds | Dec 2005 | B2 |
7008433 | Voellmicke et al. | Mar 2006 | B2 |
7044954 | Reiley et al. | May 2006 | B2 |
7048743 | Miller et al. | May 2006 | B2 |
7081125 | Edwards et al. | Jul 2006 | B2 |
7108696 | Daniel et al. | Sep 2006 | B2 |
7112205 | Carrison | Sep 2006 | B2 |
7115163 | Zimmerman | Oct 2006 | B2 |
7153306 | Ralph et al. | Dec 2006 | B2 |
7153307 | Scribner et al. | Dec 2006 | B2 |
7156861 | Scribner et al. | Jan 2007 | B2 |
7160020 | Sand | Jan 2007 | B2 |
7166121 | Reiley et al. | Jan 2007 | B2 |
7252672 | Yetkinler et al. | Aug 2007 | B2 |
7273523 | Wenz | Sep 2007 | B2 |
7361368 | Claude et al. | Apr 2008 | B2 |
7399306 | Reiley et al. | Jul 2008 | B2 |
7431763 | Zimmerman | Oct 2008 | B2 |
7448867 | Aloise | Nov 2008 | B2 |
7559932 | Truckai et al. | Jul 2009 | B2 |
7572263 | Preissman | Aug 2009 | B2 |
7662133 | Scarbrorough et al. | Feb 2010 | B2 |
7678116 | Truckai et al. | Mar 2010 | B2 |
7717918 | Truckai et al. | May 2010 | B2 |
7722620 | Truckai et al. | May 2010 | B2 |
7722624 | Boucher et al. | May 2010 | B2 |
8070753 | Truckai et al. | Dec 2011 | B2 |
8109933 | Truckai et al. | Feb 2012 | B2 |
RE43434 | Ross | May 2012 | E |
8556910 | Truckai et al. | Oct 2013 | B2 |
9066769 | Truckai et al. | Jun 2015 | B2 |
20020026195 | Layne et al. | Feb 2002 | A1 |
20020068974 | Kuslich et al. | Jun 2002 | A1 |
20020072030 | Davis | Jun 2002 | A1 |
20020147497 | Belef et al. | Oct 2002 | A1 |
20030220648 | Osorio et al. | Jan 2003 | A1 |
20030032929 | McGuckin | Feb 2003 | A1 |
20030078577 | Truckai | Apr 2003 | A1 |
20030130664 | Boucher et al. | Jul 2003 | A1 |
20030130738 | Hovda et al. | Jul 2003 | A1 |
20030195547 | Scribner et al. | Oct 2003 | A1 |
20030233096 | Osorio et al. | Dec 2003 | A1 |
20040024410 | Olson et al. | Feb 2004 | A1 |
20040073308 | Kuslich et al. | Apr 2004 | A1 |
20040083002 | Belef et al. | Apr 2004 | A1 |
20040092948 | Stevens et al. | May 2004 | A1 |
20040102845 | Reynolds | May 2004 | A1 |
20040110285 | Lendlein et al. | Jun 2004 | A1 |
20040138748 | Boyer, II et al. | Jul 2004 | A1 |
20040172132 | Ginn | Sep 2004 | A1 |
20040186576 | Biscup et al. | Sep 2004 | A1 |
20040193045 | Scarborough | Sep 2004 | A1 |
20040193171 | Dimauro et al. | Sep 2004 | A1 |
20040210231 | Broucher et al. | Oct 2004 | A1 |
20040215202 | Preissman | Oct 2004 | A1 |
20040228898 | Ross et al. | Nov 2004 | A1 |
20040267272 | Henniges et al. | Dec 2004 | A1 |
20050010231 | Myers | Jan 2005 | A1 |
20050015148 | Jansen et al. | Jan 2005 | A1 |
20050070915 | Mazzuca et al. | Mar 2005 | A1 |
20050105385 | McGill | May 2005 | A1 |
20050113843 | Arramon | May 2005 | A1 |
20050180806 | Green et al. | Aug 2005 | A1 |
20050209595 | Karmon | Sep 2005 | A1 |
20050222681 | Richley et al. | Oct 2005 | A1 |
20050245938 | Kochan | Nov 2005 | A1 |
20050251149 | Wenz | Nov 2005 | A1 |
20060052743 | Reynolds | Mar 2006 | A1 |
20060052873 | Buck et al. | Mar 2006 | A1 |
20060063126 | Aloise | Mar 2006 | A1 |
20060074433 | McGill | Apr 2006 | A1 |
20060079905 | Beyar et al. | Apr 2006 | A1 |
20060084969 | Truckai | Apr 2006 | A1 |
20060089655 | Watkins et al. | Apr 2006 | A1 |
20060052794 | McGill et al. | May 2006 | A1 |
20060100635 | Reiley et al. | May 2006 | A1 |
20060122614 | Truckai et al. | Jun 2006 | A1 |
20060122622 | Truckai et al. | Jun 2006 | A1 |
20060122623 | Truckai et al. | Jun 2006 | A1 |
20060122624 | Truckai et al. | Jun 2006 | A1 |
20060122625 | Truckai | Jun 2006 | A1 |
20060150862 | Zhao et al. | Jul 2006 | A1 |
20060182780 | Riley et al. | Aug 2006 | A1 |
20060264965 | Shadduck et al. | Nov 2006 | A1 |
20060264967 | Ferreyro et al. | Nov 2006 | A1 |
20070027230 | Beyar | Feb 2007 | A1 |
20070042016 | Nayak et al. | Feb 2007 | A1 |
20070112299 | Smit et al. | May 2007 | A1 |
20070118144 | Truckai et al. | May 2007 | A1 |
20070154874 | Sherman | Jul 2007 | A1 |
20070162043 | Truckai et al. | Jul 2007 | A1 |
20070191858 | Truckai et al. | Aug 2007 | A1 |
20070191964 | Preissman | Aug 2007 | A1 |
20070198023 | Sand et al. | Aug 2007 | A1 |
20070233148 | Truckai et al. | Oct 2007 | A1 |
20070282346 | Scribner et al. | Dec 2007 | A1 |
20080103505 | Fransen | May 2008 | A1 |
20080195112 | Liu et al. | Aug 2008 | A1 |
20080195114 | Murphy | Aug 2008 | A1 |
20080249530 | Truckai et al. | Oct 2008 | A1 |
20080300540 | Lewis | Dec 2008 | A1 |
20090024161 | Bonutti et al. | Jan 2009 | A1 |
20090084978 | Chandler | Apr 2009 | A1 |
20100110436 | Chandler et al. | May 2010 | A1 |
Number | Date | Country |
---|---|---|
2002058592 | Aug 2002 | WO |
2002064062 | Aug 2002 | WO |
2002087416 | Nov 2002 | WO |
2004075954 | Feb 2005 | WO |
2006031490 | Mar 2006 | WO |
2006062916 | Jun 2006 | WO |
2006129070 | Dec 2006 | WO |
2006130491 | Mar 2007 | WO |
2007024641 | Mar 2007 | WO |
2007028120 | Mar 2007 | WO |
Entry |
---|
Notice of Allowance dated Aug. 7, 2018 for U.S. Appl. No. 14/741,864. |
Office Action dated Jan. 30, 2018 for U.S. Appl. No. 14/741,864. |
Office Action dated Mar. 3, 2017 for U.S. Appl. No. 14/741,864. |
Office Action dated Mar. 20, 2008 for U.S. Appl. No. 11/165,652. |
Office Action dated Mar. 24, 2008 for U.S. Appl. No. 11/165,651. |
Office Action dated Mar. 24, 2009 for U.S. Appl. No. 11/165,045. |
Office Action dated Aug. 8, 2017 for U.S. Appl. No. 14/741,864. |
Office Action dated Sep. 8, 2008 for U.S. Appl. No. 11/208,448. |
Office Action dated Sep. 18, 2008 for U.S. Appl. No. 11/209,035. |
Office Action dated Sep. 19, 2008 for U.S. Appl. No. 11/196,089. |
Office Action dated Sep. 21, 2007 for U.S. Appl. No. 11/165,651. |
Office Action dated Sep. 22, 2008 for U.S. Appl. No. 11/165,651. |
Office Action dated Sep. 26, 2011 for U.S. Appl. No. 12/062,337. |
Office Action dated Oct. 3, 2007 for U.S. Appl. No. 11/165,652. |
Office Action dated Oct. 3, 2008 for U.S. Appl. No. 11/196,045. |
Office Action dated Nov. 30, 2007 for U.S. Appl. No. 11/208,448. |
Office Action, Office Action dated Sep. 19, 2008 for U.S. Appl. No. 11/165,652. ,Sep. 19, 2008 ,12 pgs. |
Carrodeguas, et al.,Injectable Acrylic Bone Cements for Vertebroplasty with Improved Properties, Journal of Biomedical Research, XP002312783, vol. 68. No. 1 ,Jan. 15, 2004 ,94-104. |
International Search Report and Written Opinion dated May 31, 2006 for PCT/US2005/044055. |
International Search Report and Written Opinion dated Sep. 11, 2008 for PCT/US2008/59305. |
Furderer, et al.,Vertebral Body Stenting. A Method for Repositioning and Augmenting Vertebral Compression Fractures, Orthopade, 31(4) ,Apr. 2002 ,356-361. |
Number | Date | Country | |
---|---|---|---|
20190167328 A1 | Jun 2019 | US |
Number | Date | Country | |
---|---|---|---|
61009671 | Dec 2007 | US | |
61009673 | Dec 2007 | US | |
61009659 | Dec 2007 | US | |
61009699 | Dec 2007 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12345937 | Dec 2008 | US |
Child | 14741864 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14741864 | Jun 2015 | US |
Child | 16200176 | US |